HOME >> MEDICINE >> NEWS
Interferon with ribavirin is safe and effective for children with chronic Hepatitis C

Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved sustained viral response, and side effects were generally mild. These results are reported in the November 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

HCV is usually asymptomatic in children though it can lead to serious liver damage. Treatment with interferon is standard and induces lasting remission in more than a third of infected children. The addition of ribavirin to treatment with interferon has been shown to markedly improve outcomes for adults with HCV, but the combination has not been extensively studied in children. Led by Regino Gonzlez-Peralta, M.D. of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition at the University of Florida, researchers addressed combination therapy for children with a twofold program.

The first part searched for the optimal dose of ribavirin for children with HCV while testing the drug's safety and efficacy. Fifty-six children, ages five to 16, were randomly assigned to take interferon along with ribavirin in varying doses for 48 weeks. They were evaluated for efficacy and side effects at regular intervals, and followed-up for an additional 24 weeks. By the end of the follow-up period, 35 percent of children taking 8 mg/kg/day of ribavirin, 37 percent taking 12 mg/kg/day, and 47 percent of 15/mg/kg/day had undetectable levels of HCV in their blood. Side effects were similar among all doses. Based on this data, the researchers selected the dosage 15 mg/kg/day for further study.

In all, 118 children with HCV received the optimized treatment
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
1-Nov-2005


Page: 1 2

Related medicine news :

1. Interferon-treated hepatitis C patients likely to experience retinopathy
2. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
3. New treatment effective in counteracting cocaine-induced symptoms
4. Osteoporosis screening and treatment may be cost-effective for selected older men
5. Study shows radiofrequency ablation highly effective in treating kidney tumors
6. New study examines effectiveness of tailored health messages
7. Scaling up HIV prevention programs is cost effective
8. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
9. U of M researchers assess effectiveness of computerized physician order entry system
10. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
11. Meningitis: effectiveness of preventive vaccination demonstrated

Post Your Comments:
(Date:7/29/2015)... ... July 29, 2015 , ... Avatar Solutions has received official ... for PQRS Survey. , The CAHPS for PQRS Survey collects information about ... or more eligible providers must participate or they will receive a 2% penalty in ...
(Date:7/29/2015)... NY (PRWEB) , ... July 29, 2015 , ... This ... on a positive surrogacy journey from a treasured member of the CARE extended family. ... Puerto Vallarta hopes to help intended parents across the globe gain a newfound perspective ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Andrzej Klos, M.D., ... Klos, a board-certified pediatrician for nearly 38 years, is motivated each and every day ... commitment to his profession shine alongside his many awards and accolades, which include multiple ...
(Date:7/29/2015)... ... , ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates studio, is ... by Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil its new ... Pilates will continue to offer the same classes and personal experiences their clients know ...
(Date:7/29/2015)... ... July 29, 2015 , ... Ticket Down is a ... Brazil vs. USA . , The international soccer schedule of matches ... exponentially and now on September 8th, one of the world’s greatest teams, Brazil, will ...
Breaking Medicine News(10 mins):Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 3Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3
(Date:7/29/2015)... N.J. and BERKELEY, Calif. ... and Plexxikon Inc., a member of the Daiichi Sankyo ... of Medicine (NEJM) published clinical trial results demonstrating ... inhibitor, induced prolonged tumor regressions in most patients with ... neoplasm of the joint or tendon sheath. ...
(Date:7/29/2015)... 2015  Hologic, Inc. (NASDAQ: HOLX ) announced ... quarter ended June 27, 2015.  Quarterly revenues of $693.9 ... on a constant currency basis.  GAAP earnings per share ... $0.43 increased 16.2%. "Our third quarter financial ... building a company that can grow sustainably on both ...
(Date:7/29/2015)... , July 29, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Monday, August 10, 2015 after the close of ... conference call and webcast on Monday, August 10, 2015 ... discuss the results and corporate developments. For ...
Breaking Medicine Technology:Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5Hologic Announces Financial Results for Third Quarter of Fiscal 2015 2Hologic Announces Financial Results for Third Quarter of Fiscal 2015 3Hologic Announces Financial Results for Third Quarter of Fiscal 2015 4Hologic Announces Financial Results for Third Quarter of Fiscal 2015 5Hologic Announces Financial Results for Third Quarter of Fiscal 2015 6Hologic Announces Financial Results for Third Quarter of Fiscal 2015 7Hologic Announces Financial Results for Third Quarter of Fiscal 2015 8Hologic Announces Financial Results for Third Quarter of Fiscal 2015 9Hologic Announces Financial Results for Third Quarter of Fiscal 2015 10Hologic Announces Financial Results for Third Quarter of Fiscal 2015 11Hologic Announces Financial Results for Third Quarter of Fiscal 2015 12Hologic Announces Financial Results for Third Quarter of Fiscal 2015 13Hologic Announces Financial Results for Third Quarter of Fiscal 2015 14Hologic Announces Financial Results for Third Quarter of Fiscal 2015 15Hologic Announces Financial Results for Third Quarter of Fiscal 2015 16Hologic Announces Financial Results for Third Quarter of Fiscal 2015 17Hologic Announces Financial Results for Third Quarter of Fiscal 2015 18Hologic Announces Financial Results for Third Quarter of Fiscal 2015 19Hologic Announces Financial Results for Third Quarter of Fiscal 2015 20Hologic Announces Financial Results for Third Quarter of Fiscal 2015 21Hologic Announces Financial Results for Third Quarter of Fiscal 2015 22Hologic Announces Financial Results for Third Quarter of Fiscal 2015 23Hologic Announces Financial Results for Third Quarter of Fiscal 2015 24Hologic Announces Financial Results for Third Quarter of Fiscal 2015 25Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015 2
Cached News: